CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease

C E Brightling, S McKenna, B Hargadon, S Birring, R Green, R Siva, M Berry, D Parker, W Monteiro, I D Pavord, P Bradding

Institute for Lung Health, Clinical Sciences Wing, University Hospitals of Leicester, Leicester, UK

Correspondence to:
Correspondence to:
Dr C E Brightling
Institute for Lung Health, Clinical Sciences Wing, University Hospitals of Leicester, Groby Road, Leicester LE3 9QP, UK; ceb17{at}le.ac.uk

Background: An association between the sputum eosinophil count and the response to a 2 week course of prednisolone has previously been reported in patients with chronic obstructive pulmonary disease (COPD). Whether the response to inhaled corticosteroids is related to the presence of eosinophilic inflammation is unclear.

Methods: A randomised, double blind, crossover trial of placebo and mometasone furoate (800 µg/day), each given for 6 weeks with a 4 week washout period, was performed in subjects with COPD treated with bronchodilator therapy only. Spirometric tests, symptom scores, chronic respiratory disease questionnaire (CRQ), and induced sputum were performed before and after each treatment phase.

Results: Ninety five patients were recruited of which 60 were randomised. Overall there were no treatment associated changes in forced expiratory volume in 1 second (FEV₁), total CRQ, or sputum characteristics. After stratification into tertiles by baseline eosinophil count, the net improvement in post-bronchodilator FEV₁ increased with mometasone compared with placebo progressively from the least to the most eosinophilic tertile. The mean change in post-bronchodilator FEV₁ with mometasone compared with placebo in the highest tertile was 0.11 l (95% CI 0.03 to 0.19). This improvement was not associated with a fall in the sputum eosinophil count.

Conclusions: An increased sputum eosinophil count is related to an improvement in post-bronchodilator FEV₁ following treatment with inhaled mometasone in COPD, but the improvement is not associated with a reduction in the sputum eosinophil count.

Abbreviations: COPD, chronic obstructive pulmonary disease; CRQ, Chronic Respiratory Disease Questionnaire; ECP, eosinophilic cationic protein; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; IL-8, interleukin 8; SOB, shortness of breath; TCC, total cell count; VAS, visual analogue score

Keywords: chronic obstructive pulmonary disease; sputum eosinophilia; inhaled corticosteroids; mometasone

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Airwaves

Wisia Wedzicha
Thorax 2005 60: 175a. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Dummer, J. F., Epton, M. J., Cowan, J. O., Cook, J. M., Condliffe, R., Landhuis, C. E., Smith, A. D., Taylor, D. R. (2009). Predicting Corticosteroid Response in Chronic Obstructive Pulmonary Disease Using Exhaled Nitric Oxide. Am. J. Respir. Crit. Care Med. 180: 846-852 [Abstract] [Full Text]  
• Taylor, D R, Pavord, I D (2008). Biomarkers in the assessment and management of airways diseases. Postgrad. Med. J. 84: 628-634 [Abstract] [Full Text]  
• Gray, R. D., MacGregor, G., Noble, D., Imrie, M., Dewar, M., Boyd, A. C., Innes, J. A., Porteous, D. J., Greening, A. P. (2008). Sputum Proteomics in Inflammatory and Suppurative Respiratory Diseases. Am. J. Respir. Crit. Care Med. 178: 444-452 [Abstract] [Full Text]  
• Borrill, Z. L., Roy, K., Singh, D. (2008). Exhaled breath condensate biomarkers in COPD. Eur Respir J 32: 472-486 [Abstract] [Full Text]  
• Pogson, Z. E. K., McKeever, T. M., Fogarty, A. (2008). The association between serum osmolality and lung function among adults. Eur Respir J 32: 98-104 [Abstract] [Full Text]  
• Kunisaki, K. M., Rice, K. L., Janoff, E. N., Rector, T. S., Niewoehner, D. E. (2008). Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: A prospective study. Ther Adv Respir Dis 2: 55-64 [Abstract]  
• Braganza, G., Chaudhuri, R., Thomson, N. C. (2008). Review: Treating patients with respiratory disease who smoke. Ther Adv Respir Dis 2: 95-107 [Abstract]  
• Vestbo, J., Anderson, W., Coxson, H. O., Crim, C., Dawber, F., Edwards, L., Hagan, G., Knobil, K., Lomas, D. A., MacNee, W., Silverman, E. K., Tal-Singer, R., on behalf of the ECLIPSE investigators, (2008). Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 31: 869-873 [Abstract] [Full Text]  
• Cazzola, M., MacNee, W., Martinez, F. J., Rabe, K. F., Franciosi, L. G., Barnes, P. J., Brusasco, V., Burge, P. S., Calverley, P. M. A., Celli, B. R., Jones, P. W., Mahler, D. A., Make, B., Miravitlles, M., Page, C. P., Palange, P., Parr, D., Pistolesi, M., Rennard, S. I., Rutten-van Molken, M. P., Stockley, R., Sullivan, S. D., Wedzicha, J. A., Wouters, E. F., on behalf of the American Thoracic Society/Europea, (2008). Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 31: 416-469 [Abstract] [Full Text]  
• Snoeck-Stroband, J. B., Lapperre, T. S., Gosman, M. M. E., Boezen, H. M., Timens, W., ten Hacken, N. H. T., Sont, J. K., Sterk, P. J., Hiemstra, P. S., the Groningen Leiden Universities Corticosteroids, (2008). Chronic bronchitis sub-phenotype within COPD: inflammation in sputum and biopsies. Eur Respir J 31: 70-77 [Abstract] [Full Text]  
• Siva, R., Green, R. H., Brightling, C. E., Shelley, M., Hargadon, B., McKenna, S., Monteiro, W., Berry, M., Parker, D., Wardlaw, A. J., Pavord, I. D. (2007). Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 29: 906-913 [Abstract] [Full Text]  
• Turino, G M (2006). Emphysema in COPD: consequences and causes.. Thorax 61: 1031-1036 [Full Text]  
• Barnes, P. J., Chowdhury, B., Kharitonov, S. A., Magnussen, H., Page, C. P., Postma, D., Saetta, M. (2006). Pulmonary Biomarkers in Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 174: 6-14 [Abstract] [Full Text]  
• Leigh, R., Pizzichini, M. M. M., Morris, M. M., Maltais, F., Hargreave, F. E., Pizzichini, E. (2006). Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 27: 964-971 [Abstract] [Full Text]  
• Brightling, C. E. (2006). Clinical Applications of Induced Sputum. Chest 129: 1344-1348 [Abstract] [Full Text]  
• O'Donnell, R, Breen, D, Wilson, S, Djukanovic, R (2006). Inflammatory cells in the airways in COPD. Thorax 61: 448-454 [Abstract] [Full Text]  
• Saha, S., Siva, R., Brightling, C. E., Pavord, I. D. (2006). COPD: an inhaled corticosteroid-resistant, oral corticosteroid-responsive condition.. Eur Respir J 27: 863-865 [Full Text]  
• Barnes, N. C., Qiu, Y.-S., Pavord, I. D., Parker, D., Davis, P. A., Zhu, J., Johnson, M., Thomson, N. C., Jeffery, P. K., on behalf of the SCO30005 Study Group, (2006). Antiinflammatory Effects of Salmeterol/Fluticasone Propionate in Chronic Obstructive Lung Disease. Am. J. Respir. Crit. Care Med. 173: 736-743 [Abstract] [Full Text]